Joel N Saltzman MD
Gastrointestinal Cancer, Genitourinary Oncology, Hematologic Oncology
Assistant Professor, Medicine, Case Western Reserve University School of Medicine
Join to View Full Profile
6780 Mayfield roadMayfield Heights, OH 44124
Phone+1 440-312-4569
Fax+1 440-312-6687
Dr. Saltzman is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Joel Saltzman is an oncologist based in Mayfield Heights, OH, specializing in gastrointestinal, genitourinary, and hematologic oncology. He completed his fellowship in hematology and medical oncology and residency in internal medicine at Case Western Reserve University/University Hospitals Cleveland Medical Center after graduating from Ohio State University College of Medicine in 1997. Dr. Saltzman has experience in a wide range of solid tumors and specializes in gastrointestinal malignancies and prostate cancer. His published work has been cited multiple times, reflecting his research on topics such as colorectal cancer and pancreatic cancer trial enrollment. He holds several CMS Meaningful Use Stage certifications achieved between 2012 and 2017.
Education & Training
Case Western Reserve University/University Hospitals Cleveland Medical CenterFellowship, Hematology and Medical Oncology, 2000 - 2003- Case Western Reserve University/University Hospitals Cleveland Medical CenterResidency, Internal Medicine, 1997 - 2000
Ohio State University College of MedicineClass of 1997
Certifications & Licensure
OH State Medical License 1998 - 2028
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification Soarian Clinicals Inpatient, Siemens Medical Solutions USA, Inc., 2012, 2014-2017
- CMS Meaningful Use Stage 2 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2017
- CMS Meaningful Use Stage 1 Certification MOSAIQ, Elekta - IMPAC Medical Systems, Inc., 2012, 2014-2017
Clinical Trials
- OPT-821 With or Without Vaccine Therapy in Treating Patients With Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Peritoneal Cancer in Second or Third Complete Remission Start of enrollment: 2010 Jul 01
- Collecting Tumor Samples From Patients With Gynecological Tumors Start of enrollment: 1992 Jun 01
Publications & Presentations
PubMed
- TP53 mutation is associated with improved disease control in patients with advanced RAS wild-type colorectal adenocarcinoma treated with cetuximab and pembrolizumab.Christos Fountzilas, Spencer Rosario, Agnieszka K Witkiewicz, Henry G Withers, David L Bajor
International Journal of Cancer. 2026-06-15 - 58 citationsEfficacy and Safety of Adagrasib plus Cetuximab in Patients with KRASG12C-Mutated Metastatic Colorectal Cancer.Rona Yaeger, Nataliya V Uboha, Meredith S Pelster, Tanios S Bekaii-Saab, Minal Barve
Cancer Discovery. 2024-06-03 - 23 citationsA Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors.Folashade Otegbeye, Brenda Cooper, Paolo Caimi, Kayla Zamborsky, Jane Reese-Koc
Transplantation and Cellular Therapy. 2022-05-01
Press Mentions
Two Phase 3 Trials at ASCO GI Support New Frontline Colorectal Cancer OptionsJanuary 9th, 2026- BRAF V600E–Mutant Colorectal Cancer: First-Line Encorafenib, Cetuximab, and FOLFIRIJanuary 6th, 2026
- Combining Encorafenib and Cetuximab with FOLFIRI May Be an Effective First-Line Treatment for Some People with Advanced Colorectal Cancer Combining Encorafenib and Cetuximab with FOLFIRI May Be an Effective First-Line Treatment for Some People with Advanced Colorectal CancerJanuary 5th, 2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
